BioAlliance Pharma expands its LoramycTM Franchise by signing a South East Asia deal worth up to $12 Million with the leading Korean Pharma Company Ha

BioAlliance Pharma's third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in Korea – the remainder being sales milestones (up to $9 million) in the designated territory and double-digit royalties commensurate with the product stage. Mr. Young-jin Kim (CEO of Handok Pharmaceuticals) said that the company plans to launch Loramyc™ in 2010.